US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Biotechnology

74.86

-0.3248-0.43%

Number of Gainers:303

Number of Losers:202

Number of Flat:11

PE:- -

High:76.12

Open:75.19

Low:74.85

Close:75.18

Volume:772.20M

Turnover:9.62B

Market Cap:1.95T

Float Cap:1.74T

Loading ...

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and PepGen Inc. (PEPG)

Anavex Life Sciences CEO Christopher U Missling to Present at TD Cowen Annual Health Care Conference

Roquefort Therapeutics to Acquire Cancer Drug AO-252 and Shift Listing to AIM

GSK to buy 35Pharma for $950 million in CEO Miel's second major deal

Morgan Stanley Trader Suggests AI Anxiety May Have Peaked, Recommends HALO Strategy for Continued Concerns

BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $98 From $95

THOMSON REUTERS

Kalamazoo Resources Wins Shareholder Backing for Capital Moves at General Meeting

Palvella Therapeutics Inc : Btig Raises Target Price to $215 From $192

THOMSON REUTERS

Vaxcyte Inc : TD Cowen Raises Target Price to $75 From $50

THOMSON REUTERS

Palvella Therapeutics Inc : TD Cowen Raises Target Price to $267 From $190

THOMSON REUTERS

ZYUS Cancels LIFE Offering, Shifts to New Financing and Expands Credit Line

Bicara Therapeutics Inc - Prices Public Offering of 7,175,000 Shares at $16.00 Each

THOMSON REUTERS

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF) and Alphatec Holdings (ATEC)

AI Era's "Scarce Assets"? Goldman Sachs: HALO—Capital-Intensive Yet Enduring

Zura Bio Ltd. Director Mark Eisner Files Initial Statement of Beneficial Ownership (Form 3)

MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale

Blowout 2025 Profit and New Drug Momentum Might Change The Case For Investing In Vertex (VRTX)

Simply Wall St.

Rosen Law Firm Urges VistaGen Investors to Act Ahead of March 16 Lead Plaintiff Deadline

ImmunityBio Director Barry J. Simon Disposes of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4139/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4139","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4139\",,,,,undefined,":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":74.85627,"timestamp":1772045389156,"preClose":75.1811,"halted":0,"volume":772201595,"delay":0,"changeRate":-0.004321,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.324829,"latestTime":"02-25 13:49:49 EST","open":75.189285,"high":76.122406,"low":74.846115,"amount":9622958391.591612,"amplitude":0.016976,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.484693,"peRate":-173.209192,"turnoverRate":0.022969,"increases":303,"decrements":202,"flats":11,"marketCap":1946309492388.5625,"floatMarketCap":1743458670772.9375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4139\",,,,,undefined,":{"symbol":"BK4139","high":76.122406,"amplitude":0.016976,"preClose":75.1811,"low":74.846115,"pbRate":"7.484693","latestPrice":74.85627,"volume":772201648,"delay":0,"open":75.189285,"prevYearClose":71.22206,"prevWeekClose":74.2994,"prevMonthClose":72.4872,"prevQuarterClose":71.2221,"fiveDayClose":74.6821,"twentyDayClose":73.8779,"sixtyDayClose":72.684,"secType":"PLATE","market":"US","turnoverRate":0.022969,"peRate":-173.209192,"marketCap":1946309492388.5625,"floatMarketCap":1743458670772.9375,"timestamp":1772045389166,"nameCN":"Biotechnology"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4139\",,,,undefined,":{"bkCode":"BK4139","up":303,"down":202,"flat":11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4139\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614470648","title":"Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614470648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614470648?lang=en_us&edition=fundamental","pubTime":"2026-02-25 15:50","pubTimestamp":1772005839,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gossamer Bio (GOSS – Research Report) and PepGen I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gossamer-bio-goss-and-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gossamer-bio-goss-and-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","BK4139","LU0029874061.USD","BK4588","BK4505","LU0128526141.USD","XBI","XLV","HCSG","LABU","BK4581","GOSS","PEPG"],"gpt_icon":0},{"id":"2614276705","title":"Anavex Life Sciences CEO Christopher U Missling to Present at TD Cowen Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614276705","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614276705?lang=en_us&edition=fundamental","pubTime":"2026-02-25 15:39","pubTimestamp":1772005196,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL7VQdC0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"gpt_icon":0},{"id":"2614755705","title":"Roquefort Therapeutics to Acquire Cancer Drug AO-252 and Shift Listing to AIM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614755705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614755705?lang=en_us&edition=fundamental","pubTime":"2026-02-25 15:31","pubTimestamp":1772004692,"startTime":"0","endTime":"0","summary":"Roquefort Investments PLC ( ($GB:ROQ) ) just unveiled an update. Roquefort Therapeutics plans to acquire worldwide exclusive rights to AO-252, a TA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/roquefort-therapeutics-to-acquire-cancer-drug-ao-252-and-shift-listing-to-aim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/roquefort-therapeutics-to-acquire-cancer-drug-ao-252-and-shift-listing-to-aim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIM","BK4007","BK4557","LENZ","BK4539","BK4139"],"gpt_icon":0},{"id":"2614866705","title":"GSK to buy 35Pharma for $950 million in CEO Miel's second major deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2614866705","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614866705?lang=en_us&edition=fundamental","pubTime":"2026-02-25 15:27","pubTimestamp":1772004467,"startTime":"0","endTime":"0","summary":"UPDATE 2-GSK to buy 35Pharma for $950 million in CEO Miel's second major deal Acquisition boosts drugmaker's pipeline of respiratory medicines 35Pharma's drug has shown promise in mouse studies for obesity-related heart conditionGSK shares have risen nearly 21% so far this year Rewrites paragraphs 1-3, adds details about 35Pharma's drug throughout and share performance in paragraph 5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL0H0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0122379950.USD","LU1228905540.USD","LU1400636657.SGD","MRK","IE00BWDBJ516.SGD","LU0965509010.AUD","GSK.UK","LU1934455863.HKD","SG9999014567.USD","SG9999014542.SGD","IE00BSNM7G36.USD","LU1069347547.HKD","LU1228905037.USD","IE00BN8TJ469.HKD","LU1023059063.AUD","LU1037948897.HKD","BK4534","LU2023250504.SGD","IE00BLSP4452.SGD","LU1974910355.USD","IE00B4R5TH58.HKD","688221","LU2125154778.USD","LU0965508806.USD","BK5011","LU0234572021.USD","LU1917777945.USD","LU1037948541.HKD","LU1989772840.SGD","SG9999001176.SGD","LU0320765489.SGD","LU0098860793.USD","RAPT","LU1309081286.SGD","LU1929549753.HKD","LU0545562505.USD","LU0320765646.SGD","IE00B3T34201.USD","LU0432979614.USD","IE00BBT3K403.USD","LU1064927863.SGD","LU0265550946.USD","LU1699723380.USD","LU0306807586.USD","SG9999015358.SGD","LU1989771016.USD","LU2125154935.USD","IE0002141913.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"1131315519","title":"Morgan Stanley Trader Suggests AI Anxiety May Have Peaked, Recommends HALO Strategy for Continued Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1131315519","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131315519?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:50","pubTimestamp":1772002254,"startTime":"0","endTime":"0","summary":"A trading desk at Morgan Stanley posits that market fears regarding artificial intelligence disrupting traditional industries may have reached their zenith. For investors who remain concerned about...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0158827948.USD","LU1732799900.SGD","LU0320765646.SGD","LU1720051017.SGD","LU1989772840.SGD","HALO","IE00BZ1G4Q59.USD","BK4585","BK4139","BK4581","LU2111349929.HKD","LU0053671581.USD","LU0971096721.USD","LU0528227936.USD","LU0225283273.USD","LU0234570918.USD","LU2271345857.HKD","LU1548497426.USD","LU2133065610.SGD","LU2028103732.USD","LU0882574139.USD","LU2023251221.USD","LU0557290698.USD","LU1244550221.USD","LU1162221912.USD","LU1732800096.USD","LU2089284900.SGD","LU0098860793.USD","LU0795875086.SGD","BK4534","LU2089283258.USD","LU0267386448.USD","BK4516","LU0106831901.USD","IE00BKVL7J92.USD","LU0314104364.USD","LU1668664300.SGD","MS","LU1989772923.USD","LU0912757837.SGD","LU2347655156.SGD","LU2357305700.SGD","BK4504","BK4588","LU0106261372.USD","LU1791710400.SGD","LU1791710582.SGD","LU1363072403.SGD","LU0158827781.USD","LU0795875169.SGD","LU0006306889.USD","LU1074936037.SGD","LU1244550494.USD","BK4127","LU1244550577.SGD","LU1720051108.HKD"],"gpt_icon":0},{"id":"2614770296","title":"BridgeBio Pharma Inc : Leerink Partners Raises Target Price to $98 From $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2614770296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614770296?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:42","pubTimestamp":1772001779,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL0M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","BK4585","BK4505","BBIO"],"gpt_icon":0},{"id":"2614774032","title":"Kalamazoo Resources Wins Shareholder Backing for Capital Moves at General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2614774032","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614774032?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:18","pubTimestamp":1771996711,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. ( ($AU:KZR) ) just unveiled an announcement. Kalamazoo Resources Ltd. has confirmed that all resolutions put to shareholde...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-wins-shareholder-backing-for-capital-moves-at-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-wins-shareholder-backing-for-capital-moves-at-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KZR","BK4139"],"gpt_icon":0},{"id":"2614774947","title":"Palvella Therapeutics Inc : Btig Raises Target Price to $215 From $192","url":"https://stock-news.laohu8.com/highlight/detail?id=2614774947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614774947?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:06","pubTimestamp":1771995975,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK17T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2614774800","title":"Vaxcyte Inc : TD Cowen Raises Target Price to $75 From $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2614774800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614774800?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:53","pubTimestamp":1771995193,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL03B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","PCVX","IE0009354923.USD","BK4139"],"gpt_icon":0},{"id":"2614711257","title":"Palvella Therapeutics Inc : TD Cowen Raises Target Price to $267 From $190","url":"https://stock-news.laohu8.com/highlight/detail?id=2614711257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614711257?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:32","pubTimestamp":1771993944,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK14R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2614280771","title":"ZYUS Cancels LIFE Offering, Shifts to New Financing and Expands Credit Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2614280771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614280771?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:32","pubTimestamp":1771993943,"startTime":"0","endTime":"0","summary":"The latest update is out from ZYUS Life Sciences ( ($TSE:ZYUS) ). ZYUS Life Sciences has cancelled its previously announced brokered LIFE private p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zyus-cancels-life-offering-shifts-to-new-financing-and-expands-credit-line?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zyus-cancels-life-offering-shifts-to-new-financing-and-expands-credit-line?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4173","BK4563","LIFE"],"gpt_icon":0},{"id":"2614718787","title":"Bicara Therapeutics Inc - Prices Public Offering of 7,175,000 Shares at $16.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2614718787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614718787?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:13","pubTimestamp":1771992786,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA4FT1HD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2614771895","title":"Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2614771895","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614771895?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:13","pubTimestamp":1771992780,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244229/0/en/Bicara-Therapeutics-Announces-Pricing-of-150-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","LU0098860793.USD","BK4516","LU2133065610.SGD","BK4585","LU0225283273.USD","IE00BKVL7J92.USD","LU1162221912.USD","LU0528227936.USD","BK4139","LU1791710400.SGD","LU2347655156.SGD","LU0795875169.SGD","LU0267386448.USD","LU2089283258.USD","LU0106261372.USD","LU1548497426.USD","LU0557290698.USD","LU0320765646.SGD","BK4534","BK4127","LU1363072403.SGD","LU1244550221.USD","LU2028103732.USD","LU2111349929.HKD","LU0158827948.USD","LU1720051017.SGD","LU0882574139.USD","BK4588","LU0006306889.USD","LU2089284900.SGD","LU1720051108.HKD","LU1732800096.USD","LU2271345857.HKD","LU0106831901.USD","LU0158827781.USD","LU1989772840.SGD","LU1791710582.SGD","LU0971096721.USD","LU1989772923.USD","USA","LU1244550494.USD","LU2023251221.USD","IE00BZ1G4Q59.USD","LU1244550577.SGD","LU1732799900.SGD","LU0314104364.USD","LU0912757837.SGD","LU0234570918.USD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2614779291","title":"Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF) and Alphatec Holdings (ATEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614779291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614779291?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:50","pubTimestamp":1771991409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiff Oncology (CRDF – Research Report) and Alphat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cardiff-oncology-crdf-and-alphatec-holdings-atec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cardiff-oncology-crdf-and-alphatec-holdings-atec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XBI","LU0566484027.USD","BK4082","XLV","ATEC","HCSG","LU1559883803.SGD","BK4139","LU0128526141.USD","BK4588","BK4581","BK4585","LABU","CRDF","BK4137"],"gpt_icon":0},{"id":"1148353877","title":"AI Era's \"Scarce Assets\"? Goldman Sachs: HALO—Capital-Intensive Yet Enduring","url":"https://stock-news.laohu8.com/highlight/detail?id=1148353877","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148353877?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:25","pubTimestamp":1771986325,"startTime":"0","endTime":"0","summary":"As AI products become increasingly easy to replicate, markets are beginning to reprice \"hard-to-replicate physical assets\" such as power grids, pipelines, infrastructure, and long-term production...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"2614277385","title":"Zura Bio Ltd. Director Mark Eisner Files Initial Statement of Beneficial Ownership (Form 3)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614277385","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614277385?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:13","pubTimestamp":1771985594,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd. filed an initial statement of beneficial ownership  reporting Mark Eisner as a director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL88rn8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2614773953","title":"MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773953","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614773953?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:09","pubTimestamp":1771985398,"startTime":"0","endTime":"0","summary":"New insider activity at MapLight Therapeutics, Inc. ( ($MPLT) ) has taken place on February 24, 2026. Director Robert C. Malenka of MapLight Therap...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/maplight-therapeutics-insider-makes-a-major-move-with-fresh-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/maplight-therapeutics-insider-makes-a-major-move-with-fresh-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"gpt_icon":0},{"id":"2614077883","title":"Blowout 2025 Profit and New Drug Momentum Might Change The Case For Investing In Vertex (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614077883","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614077883?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:26","pubTimestamp":1771982808,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals reported past full-year 2025 results with revenue rising to US$12.00 billion from US$11.02 billion and net income improving to US$3.95 billion from a US$535.60 million loss, driving basic earnings per share from a US$2.08 loss to US$15.46 in profit.\nAlongside these results, the company issued 2026 revenue guidance of US$12.95 billion to US$13.10 billion, highlighting confidence in its cystic fibrosis portfolio and emerging contributions from new products such as...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/blowout-2025-profit-and-new-drug-momentum-might-change-the-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/blowout-2025-profit-and-new-drug-momentum-might-change-the-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417517546.SGD","LU2417539215.USD","LU0432979614.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","IE00B2B36J28.USD","IE0009355771.USD","IE0002270589.USD","IE00B894F039.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","IE00B19Z9Z06.USD","LU1093756168.USD","LU2237438978.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU1674673428.USD","LU1815336091.USD","LU2236285917.USD","LU2362541513.USD","VRTX","LU1559883803.SGD","SG9999013999.USD","BK4567","LU2456880835.USD","LU0889565916.HKD","IE00B19Z3581.USD","LU1069344957.HKD","LU0234570918.USD","LU0823416689.USD","VERX","BK4023","LU1585245621.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU2462157665.USD","LU0566484027.USD","LU0256863811.USD","BK4139","SGXZ57979304.SGD","LU0079474960.USD","SG9999001176.USD","LU2362541273.HKD","BK4588","BK4585","LU0320765992.SGD","LU1093756325.SGD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2614727022","title":"Rosen Law Firm Urges VistaGen Investors to Act Ahead of March 16 Lead Plaintiff Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614727022","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614727022?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:17","pubTimestamp":1771982220,"startTime":"0","endTime":"0","summary":"Rosen Law Firm is urging investors who bought VistaGen Therapeutics common stock between April 1, 2024 and Dec. 16, 2025 to seek counsel ahead of a March 16, 2026 deadline to seek appointment as lead plaintiff in a securities class action. The suit alleges the company and certain defendants made materially false or misleading statements and concealed adverse facts about the Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder, causing investor losses when the alleged truth emerged.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL2FHqFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTGN","BK4139"],"gpt_icon":0},{"id":"2614772796","title":"ImmunityBio Director Barry J. Simon Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772796","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614772796?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:04","pubTimestamp":1771981460,"startTime":"0","endTime":"0","summary":"Barry J. Simon, a director of ImmunityBio, Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL5S3CSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ImmunityBio Director Barry J. Simon Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"gpt_icon":1}],"pageSize":20,"totalPage":128,"pageCount":1,"totalSize":2560,"code":"91000000","status":"200"}]}}